GSK said it acquired exclusive worldwide rights for a drug candidate targeting prostate cancer from France's Syndivia for up to 268 million pounds ($356.8 million).

Fresh from a European cancer conference that was all about antibody-drug conjugates (ADCs), GSK has turned to French biotech Syndivia for a preclinical prostate cancer prospect. | Fresh from a ...

Recovering from cancer, former President Joe Biden warned of “dark days” under Donald Trump, urging Americans to defend ...

Former President Joe Biden is urging Americans to stay optimistic and not to check out in response to what he says are ...